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ABBR EV I A T I ON S
AND ACRONYMS
AP = action potential
DAD = delayed
afterdepolarization
EAD = early
afterdepolarization
ECG = electrocardiography
hERG = human ether-à-go-go-
related gene
HCM = hypertrophic
cardiomyopathy
ICa-L = L-type Ca current
IK = delayed-rectifier K current
INaL = late Na current
LVOT = left ventricular
outflow tract
NCX = NaD/Ca2D exchanger
pCa = Ca activation level
RyR = ryanodine receptor
SR = sarcoplasmic reticulum
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2HIGHLIGHTS
 In patients with HCM and symptomatic LVOT-obstruction, first treatment with disopyramide leads to a marked
reduction of LVOT gradients, with a slight decrease of resting ejection fraction and a modest increase of cor-
rected QT interval, highlighting high efficacy and safety.
 In single cardiomyocytes and intact trabeculae from surgical samples of patients with obstructive HCM, in vitro
treatment with 5 mmol/l disopyramide lowered force and Ca2D transients while reducing action potential
duration and the rate of arrhythmic afterdepolarizations.
 These effects are mediated by the combined inhibition of peak and late NaD currents, L-type Ca2D current,
delayed-rectifier KD current, and ryanodine receptors.
 In addition to the negative inotropic effect of disopyramide, in vitro results suggest additional antiarrhythmic
actions.SUMMARYDep
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t reDisopyramide is effective and safe in patients with obstructive hypertrophic cardiomyopathy. However, its
cellular and molecular mechanisms of action are unknown. We tested disopyramide in cardiomyocytes from the
septum of surgical myectomy patients: disopyramide inhibits multiple ion channels, leading to lower Ca tran-
sients and force, and shortens action potentials, thus reducing cellular arrhythmias. The electrophysiological
profile of disopyramide explains the efficient reduction of outflow gradients but also the limited prolongation
of the QT interval and the absence of arrhythmic side effects observed in 39 disopyramide-treated patients. In
conclusion, our results support the idea that disopyramide is safe for outpatient use in obstructive patients.
(J Am Coll Cardiol Basic Trans Science 2019;-:-–-) © 2019 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).D isopyramide is a potent negative inotrope(1). It has been used to decrease left ventric-ular outflow tract (LVOT) obstruction in
obstructive hypertrophic cardiomyopathy (HCM)
since the first reports in the early 1980s and after
confirmatory studies of its efficacy and safety (2–6).
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3categorization as a type Ia antiarrhythmic, that is, as
Na channel blocker with action potential (AP)-pro-
longing effects (12,13). A paper in the late 1980s sug-
gested an effect on sarcolemmal Ca influx and efflux
mediated by the Naþ/Ca2þ exchanger (NCX) (14). In
light of its potent negative inotropic effects, it is not
known whether the drug has additional direct effects
on Ca2þ current, Ca2þ release from the sarcoplasmic
reticulum (SR) or on the actin-myosin interaction and
the effects of disopyramide in human HCM car-
diomyocytes have not been characterized.
We previously analyzed the electromechanical
profile of cardiomyocytes isolated from myectomy
samples of patients with obstructive HCM (15,16).
When compared with control cells, HCM car-
diomyocytes showed prolonged AP, frequent after-
depolarizations, slower Ca2þ transients, and elevated
diastolic Ca2þ concentration, largely determined by
overexpression of the late Naþ current (INaL). Indeed,
these electromechanical abnormalities were reversed
by the INaL inhibitor ranolazine, with beneficial effects
on diastolic function and cellular arrhythmias (15,16).
In the present study, we sought to uncover mecha-
nistic insights by applying electrophysiological and
biophysical techniques to evaluate the effects of dis-
opyramide on ion fluxes, afterdepolarizations, and
twitch tension in isolated HCM cardiomyocytes and
intact trabeculae harvested from patients undergoing
surgical septal myectomy. In a translational approach,
the in vitro study was combined with the first pro-
spective characterization of the electrocardiographic
and echocardiographic changes in patients with
obstructive HCM started on disopyramide treatment.
METHODS
Detailed methods are available in the Online
Appendix data supplement.
PROSPECTIVE STUDY OF PATIENTS WITH OBSTRUCTIVE
HCM TREATED WITH DISOPYRAMIDE. From October 1,
2015, to January 31, 2018, 39 patients with limiting
heart failure symptoms and elevated LVOT gradients
were initiated on sustained release disopyramide at
New York University Langone Medical Center as
previously described (4–6,9). Initial disopyramide
dosage was 250 mg twice a day, followed by drug
titration up to a maximum dosage of 300 mg every 12
h. Electrocardiography (ECG) was performed at each
visit by recording 3 12-lead 15-s strips (collected at
least 5 min apart), and QTc interval was calculated
from each strip by averaging the QT intervals
measured by a blinded operator from the 12 leads and
correcting them for heart rate using the Bazett andthe Fredericia methods. QTc values from the 3
repeated ECG strips were then averaged to obtain the
final value. Echocardiography was performed to
measure transmitral flow velocities and mitral
annular diastolic velocities and to calculate resting
LVOT gradients and LV ejection fraction before and
after disopyramide.
PATIENTS FOR STUDIES IN CELLS AND TRABECULAE.
In vitro studies were performed at the University of
Florence. Protocols were approved by the ethical
committee of Careggi University Hospital (2006/
0024713; renewed May 2009). We enrolled 20 patients
with HCM regularly followed by our Cardiomyopathy
Unit and consecutively referred to surgical myectomy
for relief of drug-refractory symptoms related to
LVOT obstruction. Among the 20 patients, 12 agreed
to undergo mutational screening in sarcomeric
genes. Clinical and genetic data are found in
Supplemental Table 1.
STATISTICS (CLINICAL STUDIES). Clinical data from
patients are expressed as mean  SD. Comparisons of
clinical variables before and after disopyramide were
performed using Student’s paired t tests. To assess
the relationship between the initial QTc and the in-
crease in QTc with disopyramide, we calculated the
Pearson correlation coefficient (r) and its significance
level using MedCalc (version 19.0; MedCalc Software,
Ostend, Belgium).
TISSUE PROCESSING AND CELL ISOLATION. Septal
specimens from 20 consecutive surgical patients were
collected from the surgeon and immediately washed
with cardioplegic solution andprocessedwithin 30min
from excision. Each sample was given a unique anon-
ymous identification number (ID 1 to ID 20). Endocar-
dial trabeculae suitable for mechanical measurements
were dissected and the remaining tissue was minced
and subjected to enzymatic dissociation to obtain
viable single myocytes, as previously described (17).
SINGLE CELL STUDIES. A perforated patch whole-
cell current clamp was used to measure membrane
potential, as previously described (15). [Ca2þ] varia-
tions were simultaneously monitored using the
Ca2þ-sensitive fluorescent dye FluoForte (Enzo Life
Sciences, Farmingdale, New York). A whole-cell
ruptured patch voltage clamp was used to record
peak and late Naþ current, L-type Ca2þ current (ICa-L),
and delayed rectifier Kþ current (IK), using appro-
priate protocols and solutions (15).
INTACT TRABECULAE STUDIES. Ventricular trabec-
ulae were mounted between a force transducer and a
motor for muscle length control (15), and isometric
force was recorded under different stimulation
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4protocols. In brief, we evaluated the inotropic re-
sponses to increased pacing frequencies and the ki-
netics of isometric twitches. Resting sarcomere
length was 1.9  0.1 mm.
DEMEMBRANATED TRABECULAE. Ventricular trabec-
ulae were skinned by exposure to 0.5% Triton X100
solution. Demembranated trabeculae were employed
to obtain calcium concentration (pCa)-tension curves
as previously described (15,18,19). Sarcomere ener-
getics was assessed in demembranated trabeculae by
simultaneous measurement of isometric force and
adenosine triphosphatase activity with an enzyme-
coupled assay (15,18,19); measurements were
repeated in the presence of disopyramide.
DRUG STUDIES. For experiments on isolated car-
diomyocytes and trabeculae, disopyramide was used
at the concentration of 5 mmol/l, unless otherwise
specified. Test recordings in presence of the drug
were performed after >3 min from the beginning of
drug exposure. Afterward, the drug was washed out
for >5 min and measurements were repeated. Of
note, all the effects of disopyramide in isolated car-
diomyocytes and trabeculae disappeared after 5 min
of drug washout.
CA2D SPARKS IN PERMEABILIZED MYOCYTES.
Ventricular myocytes were isolated from the hearts
of 4 transgenic HCM mice carrying the R92Q
troponin-T mutation, as previously described (18,19).
Myocytes were permeabilized with saponin (20) and
resuspended in an intracellular buffer containing
150 nmol/l free [Ca2þ] and 5 mmol/l of the Ca2þ-
sensitive dye Asante Naþ-green Kþ-salt (Teflabs,
Austin, Texas). The frequency of spontaneous Ca2þ
sparks was evaluated with a confocal microscope
through line scan along the longitudinal cell axis (20).
Myocytes incubated with vehicle were compared with
cells exposed to 5 mmol/l of disopyramide. The rate of
sparks was calculated from confocal line-scan re-
cordings using the SparkMaster ImageJ plugin
(National Institutes of Health, Bethesda, Maryland)
for automated analysis (21).
STATISTICS (STUDIES ON CELLS AND TRABECULAE).
None of the 20 consecutively collected patient sam-
ples was excluded from the final analysis. However,
we were unable to perform all the different experi-
mental procedures described herein in all 20 sam-
ples. Therefore, each dataset comprises results from
cells or trabeculae isolated from 3 to 11 patient
samples. For each dataset, we indicated in the
respective figure legends, the total number of cells/
trabeculae included, as well as the number (and ID)
of patients’ samples from which they were isolated.
Results from each dataset are expressed asmean  SEM. Statistical analysis, taking into account
non-Gaussian distribution, inequality of variances
and within-subject correlation, was performed as
previously described (15,18). In brief, to reduce the
risk of type I errors resulting from the stronger
interrelationship among cells/trabeculae isolated
from the same patient sample, we used hierarchical
statistics including 2 nested levels (patients and
cells/trabeculae) (22), plus a third hierarchical level
(presence or absence of disopyramide in the same
cell/trabecula) to assess the effects of drug treatment
in a pairwise fashion. This approach was imple-
mented using linear mixed models in Stata 12.0
(StataCorp LLC, College Station, Texas). The p values
were calculated using linear-mixed models. For cat-
egorical data (e.g., occurrence of cellular arrhyth-
mias), we used the Fisher exact test. We considered
p < 0.05 statistically significant.
MODELING STUDIES. Cellular mechanisms of dis-
opyramide action on dispersion of repolarization
were investigated in a population of human ventric-
ular cardiomyocyte models (n ¼ 250) in control versus
HCM remodeling, calibrated against human AP and
Ca2þ-transient data, as previously described (23).
Unpaired or paired t tests, as well as linear fitting with
r-squared calculation, were employed to analyze data
from populations of models. Mechanisms of disper-
sion at the whole ventricular level were investigated
in a cardiac magnetic resonance–based anatomical
model of a patient with obstructive HCM, under
realistic human activation sequence and heteroge-
neity in repolarizing currents (24).
RESULTS
PROSPECTIVE STUDY OF PATIENTS WITH
OBSTRUCTIVE HCM STARTED ON DISOPYRAMIDE.
Thirty-nine patients were begun on disopyramide
(age 66  10 years; 59% were female). The mean daily
dosage of disopyramide after 3 months was 497 
87 mg/day. No patient had clinically significant
arrhythmia or organ toxicity during the study period.
In 9 patients (23%), disopyramide was ineffective or
there were limiting vagolytic side effects that led to
termination of drug before 3 months.
Electrocard iograms After Disopyramide .
ECG parameters before and at a median of 96 days
after disopyramide initiation are shown in Table 1.
There were prolongations in the QTc, QRS, JT, and PR
intervals, but no significant change in heart rate at
3 months. The mean QTc interval increased from 458
 22 to 486  27 ms (p < 0.001). Mean QTc prolon-
gation was 27 ms, which corresponds to a 5.8% in-
crease from baseline. Patients with an initially longer
TABLE 1 Clinical Study: ECG
Interval (ms) JT QTc Interval (Bazett) QTc Interval (Fredericia) QRS Complex PR HR
Pre-disopyramide 354  24 458  22 453  20 103  19 179  39 64  12
4 Days 368  30 484  34 485  31 113  23 200  36 59  11
% Change þ4  2 þ5  2 þ6  2 þ9  5 þ10  7 8  3
p Value vs. pre-disopyramide <0.002 <0.001 <0.001 <0.001 <0.001 0.022
23 Days 366  30 476  37 479  34 109  26 191  32 58  10
% Change þ3  1 þ4  2 þ5  2 þ6  3 þ6  4 10  3
p Value vs. pre-disopyramide 0.002 <0.001 <0.001 0.015 <0.001 0.002
96 Days 375  35 486  27 485  24 112  23 190  33 61  11
% Change þ6  2 þ6  3 þ7  3 þ8  3 þ6  4 5  2
p Value vs. pre- disopyramide <0.001 <0.001 <0.001 <0.001 0.015 0.136
Values are mean  SD from 39 patients. The p values were calculated using paired Student’s t test. Electrocardiographic (ECG) intervals were measured before disopyramide
and after different periods from drug initiation (4, 23, 96 days), in 39 obstructive hypertrophic cardiomyopathy patients. QTc was determined using Bazett formula or Fredericia
formula.
HR ¼ heart rate; JT ¼ time from the end of the QRS complex to the end of the T wave; PR ¼ time from the beginning the P wave to the beginning of the QRS complex.
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5QTc interval (greater than the median 457 ms) had a
smaller increase in QTc interval than did patients
with shorter initial QTc interval (DQTc: 18  4 vs. 34
 8 ms, p ¼ 0.007). There was an inverse correlation
between the initial QTc interval and the increase
in QTc interval with disopyramide (Pearson
r ¼ 0.44, p ¼ 0.008).
Echocard iography . Initial resting LVOT gradients
were 58  49 mm Hg. After 96 days of disopyramide,
gradients were reduced to 25  26 mm Hg (p < 0.001).
There were no differences in tissue Doppler variables,
transmitral flow velocities, and in the calculationsTABLE 2 Clinical Study: Echocardiography
Doppler Veloc
Septal TDI e0 (e0S) Latera
Pre-disopyramide 4.3  0.8 6
Post-disopyramide 4.1  1.0 6
% Change 5  15 
p Value 0.184
Diastolic Function
Septal E/e’
Pre-disopyramide 21.2  8.7
Post-disopyramide 20.7  7.6
% Change 3  22
p Value 0.915
Systolic F
LVEDV (ml)
Pre-disopyramide 60.5  18.2
Post-disopyramide 63.2  21.5
% Change þ5  26
p Value 0.182
Values are mean  SD from 39 patients. The p values were calculated using paired St
disopyramide initiation (pre-disopyramide) and at the end of study (post-disopyramide)
LVEDV ¼ left ventricular end-diastolic volume; LVEF¼ ejection fraction; LVESV ¼ end-
(free wall) mitral annulus measured at tissue Doppler; Septal TDI e0 (e0S) ¼ early diastolic
Transmitral A ¼ late diastolic transmitral flow velocity (during atrial systole); Transmitrfrom tissue Doppler and transmitral flow velocities
used to estimate left atrial pressure (Table 2). Ejection
fraction was minimally reduced by disopyramide
from 72.2% to 68%, an average decrease by 5.8  3.1%
(Table 2).
IN VITRO STUDY ON HUMAN MYOCARDIUM. Samples
from 20 patients with HCM undergoing surgical
myectomy for drug-refractory symptoms were
assessed. Clinical data at pre-operative assessment
are shown in Supplemental Table 1.
Disopyramide Reduces Force and Accelerates
the Kinet i cs of I sometr i c Twitches . Disopyramideities (cm/s)
l TDI e0 (e0L) Transmitral E Transmitral A
.5  2.0 85  28 85  20
.0  1.9 82  23 90  30
8  25 3  16 þ5  21
0.125 0.693 0.442
: Calculations
Lateral E/e’ E/(e0Sþe0L/2)
13.8  7.9 11.7  5.4
13.9  9.1 11.5  5.3
0  17 1  14
0.643 0.894
unction
LVESV (ml) LVEF (%)
17.0  6.2 72.2  5.0
20.2  7.3 68.0  3.5
þ15  27 6  3
0.001 <0.001
udent’s t test. Comparison between echocardiographic parameters obtained before
.
systolic volume; Lateral TDI e0(e0L) ¼ early diastolic downward velocity of the lateral
downward velocity of the medial (septal) mitral annulus measured at tissue Doppler;
al E ¼ early diastolic flow velocity through the mitral valve.
FIGURE 1 Effects of Disopyramide in Myocardial Mechanics in Intact and Skinned Trabecuale
(A) Representative superimposed force twitches elicited at 0.5 Hz in hypertrophic cardiomyopathy (HCM) trabeculae in the absence (black trace) and presence (blue
trace) of disopyramide 5 mmol/l (Diso). (B) Relationship between the negative inotropic effect of disopyramide and its concentration in the extracellular fluid;
calculated concentration at which 50% of the maximal effect is obtained (EC50) is shown. Means  SEM from 5 trabeculae, 5 patients. (C) Time from stimulus to peak
and time from peak to 50% relaxation (RT50%) of force twitches elicited at 1 Hz at baseline (black) and in the presence of disopyramide (blue). (D) Effects of
disopyramide at different stimulation frequencies. Disopyramide slightly reduces the slope of force-frequency relationship at higher pacing rates. (C,D) Means  SEM
from 13 trabeculae, 10 patients (ID 1, 2, and 5 to 12). (E) Disopyramide in skinned trabeculae from patients with HCM. As shown in these superimposed traces from an
HCM trabecula, disopyramide does not reduce isometric force at intermediate Ca activation level (pCa 6) or at maximal myofilament activation (pCa 4.5). (F) Maximal
tension and pCa at one-half of maximal tension (Ca sensitivity) in HCM trabeculae, in the absence and presence of disopyramide. Means  SEM from 6 trabeculae, 3
patients (ID 12, 15, and 16). (C,D,F) *0.05 > p > 0.01; **0.01 > p > 0.001; ***p < 0.001; linear-mixed models. bpm ¼ beats/min.
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FIGURE 2 Effects of Disopyramide on Intracellular Ca2þ
(A) Representative intracellular Ca2þ traces recorded during regular stimulation at 0.2, 0.5, and 1 Hz, in the absence (left, black) and presence of disopyramide
5 mmol/l (Diso) (blue traces on the right). (B) Percentage of variation of diastolic [Ca2þ]i, and Ca-transient amplitude (Systolic Ampl) with the application of
disopyramide 5 mmol/l with respect to baseline in hypertrophic cardiomyopathy cardiomyocytes, during regular stimulation at 0.2, 0.5, and 1 Hz at steady state.
(C) Representative superimposed action potentials (top) and simultaneously recorded Ca transients (bottom) at baseline (black traces) and in the presence of
disopyramide (blue traces), elicited at 0.2 Hz (left) and 0.5 Hz (right). (D) Time from peak to 50% decay of Ca transients at baseline (black) and in the
presence of disopyramide 5 mmol/l (blue), elicited at 0.2, 0.5, and 1 Hz. (B–D) Means  SEM from 26 cardiomyocytes from 7 patients with hypertrophic
cardiomyopathy (ID 5 to 9 and 11 to 13). *0.05 > p > 0.01; **0.01 > p > 0.001; linear-mixed models. MP ¼ membrane potential.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . - , N O . - , 2 0 1 9 Coppini et al.
- 2 0 1 9 :- –- Disopyramide in HCM: Cellular Mechanisms
7was added to standard perfusion solution while
recording isometric tension from intact contracting
trabeculae dissected from the endocardial surface.
As expected, the drug displayed a consistent
negative inotropic effect (Figure 1A). To assess the
concentration dependency of this effect, we exposed
the muscles to different concentrations of dis-
opyramide (Figure 1B). Calculated disopyramide con-
centration at 50% of maximal effect on isometric
twitch amplitude was 5.29  1.55 mmol/l. We therefore
decided to employ the drug at 5 mmol/l for all the
following experiments; notably, 5 mmol/l corresponds
to the average plasma concentration of disopyramide
measured in patients under a standard treatment
regimen (25). Importantly, 5 mmol/l disopyramide
hastened isometric twitch kinetics in HCM trabeculae:
both time to peak and relaxation time were reversibly
shortened by the application of the drug (Figures 1Aand 1C). We tested the effects of disopyramide at
different stimulation frequencies (Figure 1D): the
reduction of steady-state isometric twitch force was
more pronounced at higher pacing rates as compared
with lower rates. Isometric twitch force was reduced
by 33  5% at 0.5 Hz (30 beats/min) and by 62  10% at
1.5 Hz (90 beats/min; p ¼ 0.015 vs. 0.5 Hz; data from 13
trabeculae in 10 patients, calculated using linear-
mixed models).
Disopyramide Has No Direct Effects on Myofilament
Contraction.We tested the effects of disopyramide on
demembranated trabeculae from 3 patients with HCM
(Figure 1E). Disopyramide (5 mmol/l) did not affect
maximal force obtained when exposing trabeculae to
an activating solution with pCa 4.5 (Figure 1F). Force
generation at lower [Ca2þ], determining submaximal
tension development, was also unaffected by dis-
opyramide; we concluded that disopyramide does
TABLE 3 Effects of Disopyramide on AP and [Ca2þ]i
0.2 Hz Baseline Disopyramide % Change p Value
[Ca2þ]i, nmol/l
Diastolic Ca 235  44 189  31 22  8 0.015
Ca2þ -transient amplitude 336  53 188  34 44  15 0.006
Ca2þ -transient kinetics, ms
Time to peak 151  15 128  12 15  8 0.024
90% Decay 1,260  99 905  88 28  8 0.008
Action potentials
MDP, mV 80  3 80  3. 0  3 >0.05
Amplitude, mV 129.1  3.2 122.2  2.8 5  1 0.012
Upstroke, V/s 139  18 97  12 30  9 0.002
APD20, ms 381  44 284  40 25  9 0.017
APD50, ms 653  63 469  61 28  7 <0.001
Values are mean  SEM. The p values were calculated using linear mixed models. Additional data from action
potentials and Ca transients were recorded in hypertrophic cardiomyopathy cardiomyocytes stimulated at 0.2 Hz
before and during exposure to disopyramide. Data from 28 HCM cardiomyocytes isolated from 8 hypertrophic
cardiomyopathy patient samples (ID 3 to 6, 9, and 11 to 13). Diastolic Ca is the diastolic concentration of Ca during
regular stimulation. Ca2þ-transient amplitude is the difference between peak systolic Ca and diastolic Ca. Time to
peak is the measurement from stimulus to peak. The 90% decay is the time from peak to 90% decay of Ca
transients. Upstroke is the upstroke speed of the action potentials.
APD20 (APD50) ¼ action potential duration at 20% (50%) of repolarization; MDP ¼ mean diastolic potential.
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8not modify myofilament Ca sensitivity (Figure 1F).
Moreover, disopyramide did not alter the energy cost
of tension generation (Supplemental Figure 1). The
same results were obtained in demembranated
trabeculae from healthy donors.
Disopyramide Reduces Diastolic Ca2D and Hastens the
Kinetics of Ca2D Transients. Disopyramide was tested at
5 mmol/l in patch-clamped ventricular car-
diomyocytes while simultaneously recording Ca2þ
transients and AP during stimulation at different
frequencies (Figures 2A and 2C). The drug reduced the
amplitude of Ca2þ transients at all frequencies
(Figure 2B), hastened the kinetics of Ca2þ transient
rise and decay (Figures 2C and 2D, Table 3) and
reduced diastolic Ca2þ concentration (Figures 2A and
2B, Table 3).
Disopyramide Reduces AP Duration and the Frequency
of Afterdepolarizations. Disopyramide (5 mmol/l)
shortened the duration of AP in HCM cardiomyocytes
(Figures 2C and 3A, Table 3) at all frequencies
(Figure 3B) and the effect was more pronounced at
lower rates. For instance, average AP shortening at
0.1 Hz was 27  5% and is comparable to that observed
in human HCM cardiomyocytes with 10 mmol/l of
ranolazine (17). In addition, disopyramide reduced AP
amplitude and upstroke speed (Table 3). Finally, dis-
opyramide reduced the incidence of spontaneous
afterdepolarizations in HCM cardiomyocytes, both
early afterdepolarizations ([EAD], occurring during
the AP plateau) and delayed afterdepolarizations
([DAD], occurring during the diastolic phase),
occurring during 3 min of regular stimulation
(Figures 3C and 3D).Disopyramide Inhibits Peak and Late NaD, Ca2D, and
KD Currents.We previously have shown that in HCM
cardiomyocytes there is markedly enhanced INaL,
slightly increased ICa-L, and lower IK, leading to pro-
longed AP duration (15). We assessed Naþ currents in
HCM cardiomyocytes during voltage clamp on depo-
larization to 10 mV. Peak current was measured in
the first 10 ms of depolarization (Figure 4A), whereas
INaL was estimated by integrating the residual inward
current (50 to 800 ms after onset) (Figure 4B). In HCM
myocytes, disopyramide (5 mmol/l) reduced peak Naþ
current by 22  4% and greatly decreased INaL integral
by 45  6% (21 myocytes, 5 patients).
We then assessed the effects of disopyramide on IK,
measured at steady state during depolarization at
different potentials (Figure 4C). Disopyramide
(5 mmol/l) exerted a small but significant inhibitory
effect on IK currents in HCM cardiomyocytes
(Figure 4D). Notably, the density of steady-state IK at
baseline is reduced in our HCM myocytes as
compared with control myocardium (Supplemental
Figure 2). Moreover, disopyramide reduced the
amplitude of ICa-L in HCM cardiomyocytes (Figures 4E
and 4F); the average ICa-L reduction was 16  4%
(mean of 16 myocytes from 4 patients).
Taken together, the observed effects of dis-
opyramide on Naþ, Kþ, and Ca2þ currents explain the
net reduction of AP duration by disopyramide
(Figure 3). In HCM septal cells, in the presence of
lower IK (15), slightly increased ICa-L, and markedly
enhanced INaL, the effect of disopyramide is a net
decrease of depolarizing currents, ultimately leading
to AP shortening. On the contrary, in control human
ventricular myocytes, where the expression of IK is
preserved and INaL is small (15), inhibition of human
ether-à-go-go-related gene (hERG) Kþ current by
disopyramide (26) prevails over the reduction of ICa-L
and INaL, ultimately leading to a slight AP prolonga-
tion (Supplemental Figure 3), in agreement with
previous reports (27).
Disopyramide Inh ib i ts RyR. Similar to other class I
antiarrhythmics (28), disopyramide exerts an inhibi-
tory effects on the ryanodine receptor (RyR). We
tested the effects on RyR channels by evaluating the
rate of Ca sparks in permeabilized ventricular myo-
cytes isolated from a transgenic HCM mouse model
carrying the R92Q-TnT mutation (Figure 5A). The
frequency of Ca2þ sparks in myocytes incubated with
5 mmol/l of disopyramide was lower than that
observed in vehicle-treated cells (Figure 5B).
DISOPYRAMIDE DECREASES VENTRICULAR
DISPERSION OF REPOLARIZATION IN SILICO. The
effects of 5 mmol/l of disopyramide were modeled in
silico based on the above-mentioned characterization
FIGURE 3 Effects of Disopyramide on AP and Cellular Arrhythmias
(A) Representative superimposed action potentials (AP) at baseline (black traces) and in the presence of disopyramide 5 mmol/l (Diso) (blue traces), elicited at 0.2 Hz
(left) and at 1 Hz (right). (B) Action potential duration at 90% of repolarization (APD90%) at baseline (black) and in the presence of disopyramide (blue). (C)
Representative action traces at baseline (black traces) and in the presence of disopyramide 5 mmol/l (blue traces), elicited at 0.2 Hz pacing rate. Disopyramide sup-
presses early afterdepolarizations (EAD) (arrows). (D) Percentage of HCM cardiomyocytes showing at least 2 EAD or delayed afterdepolarizations (DAD) during 3 min
of continuous stimulation, at baseline (black) and in the presence of disopyramide (blue). (B,D) Means  SE from 28 hypertrophic cardiomyopathy cardiomyocytes
from 8 patients with hypertrophic cardiomyopathy (ID 3 to 6, 9, and 11 to 13). **0.01 > p > 0.001; ***p < 0.001; linear-mixed models.
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9of drug action. In agreement with the experimental
findings, 5 mmol/l of disopyramide yielded AP short-
ening in HCM endocardial cardiomyocytes and left
AP duration unaltered in control endocardium
(Figures 6A and 6B). Due to transmural differences in
ion channel expression, this trend was reversed in
epicardial cardiomyocytes, where disopyramide
slightly prolonged AP duration in control cells
(Figures 6A and 6B). The magnitude of AP duration at
90% of repolarization shortening in HCM endocardial
cells was inversely correlated with basal AP duration
at 90% of repolarization (Figure 6C). Further analysis
of responders to drug action indicates that INaL den-
sity is the primary determinant of the extent of AP
shortening due to disopyramide (Figure 6D).
In the reconstructed ventricles of a patient with
obstructive HCM, 5 mmol/l disopyramide reduced
conduction velocity, increasing total activation time
by 11 ms (Supplemental Figure 4), comparable toclinical data (QRS prolongation at ECG, see Table 1). In
the region of septal hypertrophy, 5 mmol/l of dis-
opyramide markedly decreased dispersion of repo-
larization times (baseline: 529  62 ms, 625 ms
maximum; 5 mmol/l of disopyramide: 504  50 ms,
585 ms maximum) and slightly prolonged repolari-
zation in the nonhypertrophic epicardium (Figure 6E).
This heterogeneous ventricular action resulted in
QT shortening in septal precordial ECG leads along
with modest QT prolongation in the lateral ones
(Figure 6E), hence explaining the apparent discrep-
ancy between AP shortening and the clinical QTc
prolongation observed in patients with HCM
following disopyramide intake.
DISCUSSION
In the present work, we have investigated the effects
of disopyramide in patients with obstructive HCM
FIGURE 4 Effects of 5 mmol/l Disopyramide on Ion Channels
(A, left) Representative peak Na current traces elicited at 10 mV from 120 mV resting potential, in a hypertrophic cardiomyopathy cardiomyocyte in the absence
(black) and presence of disopyramide (Diso) (blue trace). (Right) Average peak Naþ current (INa-peak) density at 10 mV; effect of disopyramide. (B, left) Repre-
sentative late Naþ current (INaL) traces elicited at -10 mV from 120 mV resting potential, in the absence and presence of disopyramide. (Right) Average integral of the
area of the current between 50 and 750 ms after onset of the 10 mV clamp pulse, normalized by cell capacitance, calculated in the absence and presence of
disopyramide in hypertrophic cardiomyopathy cardiomyocytes. (A,B) Means  SEM from 22 cardiomyocytes, 5 patients (ID 14 to 18). *0.05 > p > 0.01;
**0.01 > p > 0.001; linear-mixed models. (C) Delayed-rectifier K currents (IK) elicited at different voltages in hypertrophic cardiomyopathy cardiomyocytes (see inset
for color codes), in the absence of disopyramide (left) and in its presence (right). (D) Average IK current density in the absence and presence of disopyramide at different
voltages. Mean  SEM from 10 cardiomyocytes, 4 patients (ID 14, 16, 19, and 20). ‡p < 0.05 for voltages $þ20 mV, linear-mixed models used to compare each
coupled pair of values. (E) Representative L-type Ca2þ current (ICa-L) traces elicited at 0 mV from 80 mV resting voltage. (F) Average ICa-L current density in the
absence and presence of disopyramide at different voltages. Mean  SEM from 12 cardiomyocytes, 3 patients (ID 15, 17, and 18). §p < 0.05 for voltages between
10 mV and þ30 mV, linear-mixed models.
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FIGURE 5 Effects of 5 mmol/l of Disopyramide on Ca Sparks in Permeabilized Myocytes
(A) Calcium sparks in permeabilized cardiomyocytes from the left ventricle of transgenic hypertrophic cardiomyopathy mice (R92Q-TnT mu-
tation): the representative kymographic images show confocal line scans traced along the longitudinal cell axis, displaying fluorescence signals
from the Ca-selective dye, recorded at a speed of 512 lines/s while bathing the permeabilized myocytes in an intracellular solution containing
150 nmol/l [Ca2þ] at room temperature. Spontaneous Ca sparks are visible as spontaneous elevations of local [Ca2þ] signal lasting 20 to 40ms.
Representative traces from cells in the absence (left) and presence of disopyramide (Diso) (right) in the bathing solution. Kymographic images
are reported in false color (16-colors lookup table) after thresholding and filtering (Gaussian smoothing with 2px sigma). (B) Frequency of
spontaneous Ca sparks per 100 mmol/l of scanned line length, in the absence and presence of 5 mmol/l disopyramide. Mean  SEM from 74
cardiomyocytes (basal) and 63 cardiomyocytes (disopyramide) isolated from 4 mouse hearts. **0.01 > p > 0.001, unpaired Student’s t test.
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11and on isolated HCM cardiomyocytes harvested from
patients undergoing surgical septal myectomy. The
results shed light on the agent’s biophysical mecha-
nisms of benefit, and its demonstrated clinical safety
in patients with HCM. In addition, the suppressive
effect of disopyramide on afterdepolarizations
in vitro raises the possibility that disopyramide may
reduce ventricular arrhythmia propensity in vulner-
able patients with HCM.
NEGATIVE INOTROPIC EFFECT IN OBSTRUCTIVE
PATIENTS. In patients with obstructive HCM, the
beneficial effect of disopyramide is that it decreases LV
contractility, specifically by decreasing early LV ejec-
tion flow acceleration (29). In patients with obstructive
HCM, the mitral valve apposes with the septum very
early in systole, and the duration of mitral-septal
contact correlates with gradient magnitude, because
of the amplifying feedback loop in which the presence
of a gradient pushes the valve further into the septum.
Thus, to reduce obstruction-related gradients, the
impact of any negative inotropic medication must be
very early in systole, before the onset mitral-septal
contact. By decreasing early systolic ejection acceler-
ation, disopyramide decreases early drag forces on the
mitral valve, delaying or abolishing mitral-septal
contact. Systolic anterior motion results from an
equilibrium between the displacing anteriorly
directed force of ejection flow striking themitral valve,
versus restraining forces, from the papillary muscles
and chordae (30). Disopyramide displaces this equi-
librium toward restraint by dint of its effects on early
flow acceleration. Interestingly, despite the decreasedvelocity of pressure generation (dP/dt) during early
systole and the lower peak LV pressure, disopyramide
results in a modest reduction of global systolic func-
tion (5% to 6% decrease of ejection fraction in our
study, in line with previous observations). In normal
subjects, disopyramide causes a prolongation of total
ejection time (1); in subjects with HCM, however,
where ejection time is prolonged due to obstruction,
the relief of obstruction by disopyramide leads to a 12%
shorter ejection time (31). Moreover, disopyramide has
a more potent gradient-lowering effect than other
negative inotropic agents given for obstructive HCM
(beta blockers and verapamil). In a head-to-head
comparison in individual patients with HCM by intra-
venous administration of the 3 agents on sequential
days, investigators found a 59% reduction of gradient
with disopyramide, a 19% reduction with propranolol,
and only 8% reduction with verapamil (11,32). On
average, 60% to 70% of patients started on dis-
opyramide will experience a significant drop in LVOT
gradient and improvement in symptoms (5,6).
Whereas the gradient-lowering effect of disopyramide
shows a clear dependency on dose and plasma levels
(1,3,33), the negative inotropic effect is always very
modest and does not vary within the clinically relevant
range of doses (up to 300 mg twice daily). These ob-
servations suggest that symptomatic gradients can be
effectively lowered by negative inotropic agents
without largely reducing ejection fraction. This may
be related to the fact that most patients with obstruc-
tive HCM are pathologically hyperkinetic. In HCM
hearts, negative inotropic drugs may counteract LV
FIGURE 6 Modeling Results on the Action of Disopyramide on the Dispersion of Repolarization
(A) Representative superimposed action potentials at baseline (black traces) and in the presence of disopyramide 5 mmol/l (blue traces) in endocardial (Endo) and
epicardial (Epi) models of human ventricular cardiomyocytes at 1 Hz pacing. (B) APD90% at baseline (black) and in the presence of disopyramide 5 mmol/l (blue), for
the different cell types. *p < 0.05, paired Student’s t test. (C) Endocardial APD shortening in HCM endocardial cardiomyocytes under disopyramide 5 mmol/l action as a
function of baseline APD90%. (D) Cellular mechanisms underlying endocardial APD shortening in responders (dark blue) versus nonresponders (light blue) to
disopyramide. *p < 0.05, unpaired Student’s t test. (E) RT90% in a ventricular model of obstructive HCM. Disopyramide reduces maximum dispersion of repolar-
ization in the septal hypertrophic region while only slightly prolonging repolarization in nonhypertrophic epicardium, leading to QT shortening in septal compared with
modest QT prolongation in lateral precordial electrocardiogram leads (V1 and V5 shown). CTRL ¼ control model; IKr ¼ rapid delayed-rectifier Kþ current;
RyR ¼ ryanodine receptor; other abbreviations as in Figures 1 to 4.
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12hypercontractility and reduce early ejection accelera-
tion while at the same time allowing a more efficient
LV emptying due to loss of obstruction. Thus, the
impact of negative inotropic drugs on end-systolicvolume will be very limited, explaining the modest
reduction of ejection fraction.
In the current study, disopyramide lowered resting
LVOT gradients from mean 58 to 25 mm Hg after
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133 months. This was similar to a prior report in 221
patients using disopyramide with an average dose of
500 mg/day, where resting LVOT gradients decreased
from 63 to 25 mm Hg after 4.5 years (6). Symptoms
and gradient in 64% of patients of this cohort could
be managed pharmacologically, while 36% ultimately
underwent septal reduction.
CELLULAR MECHANISMS UNDERLYING THE NEGATIVE
INOTROPIC ACTION OF DISOPYRAMIDE. Our in vitro
force assessments using human HCM samples confirm
the negative inotropic action of disopyramide
observed in patients. The results of our studies show
that this effect is the result of the inhibitory action of
disopyramide on multiple ion channels within
the cardiomyocyte.
Disopyramide Has No Direct Effects on Myofilaments.
Disopyramide does not modify the maximal force
generated by the contractile apparatus in HCM and
control trabeculae, and it does not change myofila-
ment sensitivity to Ca2þ, suggesting that the drug does
not directly target contractile proteins (Figure 6).
Therefore, disopyramide must reduce force through
modifications of the cardiomyocyte excitation-
contraction coupling, that is, intracellular Ca2þ
handling. By contrast, mavacamten (MYK-461) pro-
duces a negative inotropic effect by virtue of direct
inhibitor of cardiac myosin (34) with no apparent off-
target side effects. Mavacamten was recently tested
in a small number of patients with obstructive HCM in
a phase II study, showing that a clinically meaningful
reduction of post-exercise LVOT gradients can be
achieved with relatively small doses of the drug, while
leading to a modest reduction of LV ejection fraction,
on the order of 6% to 10% on average. This is in line
with the idea that a large reduction of LVOT gradients
in patients with obstructive HCM can be achieved us-
ing negative inotropic drugs with a minimal loss of
global LV function.
Disopyramide Reduces the Amplitude of Calcium
Transients. The negative inotropic effect of dis-
opyramide is a consequence of the reduction of sys-
tolic intracellular Ca2þ levels in the cardiomyocyte,
thus determining lower Ca-mediated activation of
myofilaments and, ultimately, lower force. We found
a number of concurrent mechanisms contributing to
the reduction of Ca2þ-transient amplitude.
Disopyramide Reduces Peak NaD Current and
INaL . Early studies demonstrated that Naþ channel
block (e.g., by tetrodotoxin) has a slight negative
inotropic action per se in the myocardium. Interest-
ingly, these studies compared the negative inotropic
potency of different drugs with their efficacy in slow-
ing down AP upstroke (a direct consequence of peak
Naþ-current inhibition) (35,36). The ratio of negativeinotropic efficacy versus Naþ-channel blocking po-
tency was the lowest for tetrodotoxin (0.23) and the
highest for disopyramide (2.2). Disopyramide has the
most negative inotropic effect of all Class I antiar-
rhythmics, higher than mexiletine, procainamide, and
quinidine (35). As tetrodotoxin is a pure Naþ-channel
blocker, these results suggest that Naþ-channel inhi-
bition only slightly contributes to the negative
inotropic action of disopyramide, and that dis-
opyramide has additional Naþ-channel–independent
mechanisms that make it the most potent negative
inotropic agent among class I antiarrhythmics (35).
Nonetheless, Naþ-channel inhibition may inde-
pendently contribute to the reduction of Ca2þ-
transient amplitude by disopyramide through
modification of the activity of the NCX (37). When
membrane potential is positive (peak and plateau of
the AP) and subsarcolemmal [Naþ] is high (due to
large Naþ influx by peak INa), NCX works in reverse
mode, in other words, letting Ca2þ enter the cell in
exchange for Naþ (38). The contribution of reverse-
mode NCX to Ca2þ transients is particularly high in
HCM cardiomyocytes (16). In the presence of peak
and late INa inhibition by disopyramide, maximal AP
voltage is reduced (Table 2) and intracellular [Naþ] is
diminished (16): these changes lead to a decrease of
reverse-mode NCX activity, thus reducing Ca2þ entry
(39). Moreover, reduction of diastolic [Naþ] may
enhance the diastolic extrusion of Ca2þ via the NCX
(forward mode) (15,18). The 2 mechanisms (reduced
reverse- and enhanced forward-mode NCX) may
contribute to reduce total Ca2þ load of the SR (15) and
thus Ca2þ-transient amplitude. Selective inhibition of
INaL without block of peak INa (e.g., with ranolazine or
eleclazine) is not sufficient to induce a negative
inotropic effect under basal conditions (15,16).
Therefore, we can conclude that simultaneous inhi-
bition of peak and late INa is required for the negative
inotropic action of disopyramide.
Disopyramide Reduces I C a - L . Disopyramide exerts
a slight but relevant inhibitory effect on ICa-L, which is
substantially lower than that of verapamil. Nonethe-
less, the observed 15% inhibition of peak ICa-L by
disopyramide contributed to reduce Ca2þ-transient
amplitude in ventricular myocytes, the effect being
larger at higher stimulation rates. A similar rate-
dependency of the negative inotropic effect is
typical of pure Ca2þ-channel blockers such as verap-
amil (40). At variance with verapamil (41), however,
disopyramide has minimal effects on heart rate and
atrioventricular conduction (Table 3), and thus can be
safely combined with -beta blockers.
Disopyramide Inh ib i ts RyR. Naþ channel blockers
flecainide and propafenone stabilize the closed state
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14of cardiac RyR channels (42). We observed that dis-
opyramide reduced the rate of spontaneous Ca2þ
sparks in permeabilized myocytes, in the presence of
fixed intracellular [Ca2þ]: the reduction in the spon-
taneous RyR opening rate is likely due to a direct ef-
fect of disopyramide on RyR channels. Notably,
selective inhibition of RyR channels using JTV-519 in
human ventricular trabeculae led a slight negative
inotropic effect (43). Similarly, inhibition of RyR-
mediated systolic Ca2þ release by disopyramide may
contribute to the reduction of Ca2þ-transient
amplitude.
DISOPYRAMIDE SHORTENS REPOLARIZATION IN HCM
CARDIOMYOCYTES: MOLECULAR MECHANISMS. Early
studies in healthy myocardium showed that dis-
opyramide prolongs ventricular AP (13) due to
decreased IKr current by direct inhibition of hERG
channels (44). Similarly, we observed a slight AP pro-
longation in cardiomyocytes from patients without
HCM (Online Figure 3), also confirmed by modeling
studies (Figure 6A). Interestingly, the AP prolonging
effect in control cardiomyocytes was shown to be
prevalent at concentrations below 8 mmol/l, whereas at
higher concentrations, disopyramide tended to
shorten AP (13,45). At low concentrations, hERG inhi-
bition prevails over INaL and ICa-L block, leading to a net
decrease of repolarizing currents and AP prolongation;
at higher concentrations, however, after maximal
hERG inhibition is reached, the inhibition of depola-
rizing Ca2þ and Naþ currents becomes prevalent,
leading to AP shortening in healthy myocardium.
Based on our observations, we can speculate that the
latter behavior occurs in HCM cardiomyocytes even
at low, clinically relevant concentrations (such as
5 mmol/l, which we used in this work), due to the
decreased expression of hERG channels in HCM
myocardium (15). Moreover, INaL and ICa-L are both
increased in HCM versus control myocardia (15);
therefore, their inhibition by disopyramide leads to
greater AP shortening, especially at low pacing rates.
Simulation studies suggested that AP shortening by
disopyramide is more pronounced in cells that have
larger INaL and smaller IKr (Figures 6C and 6D). Taken
together, the altered balance of depolarizing and
repolarizing currents in cardiomyocytes from the
hypertrophic septum of patients with HCM causes
disopyramide to decrease net depolarizing currents
(Naþ and Ca2þ) without substantial reduction in
repolarizing Kþ currents, ultimately shortening AP
plateau duration (Figure 2, Table 1).
SHORTENING OF AP DURATIONANDQTc PROLONGATION:
AN APPARENT CONTRAST. In the 39 patients begun on
disopyramide, QTc interval increased from 458  22 to486  27, an average 5.8% rise after 3 months. The
shortening of AP observed in HCM cardiomyocytes
in vitro is in apparent contrast with the slight QTc
prolongation in patients. However, prolongation of
QTc interval with disopyramide depends, at least in
part, on the prolongation of QRS interval, reflecting
delayed intraventricular electrical conduction velocity
due to peak Naþ-current inhibition (Table 1) (46).
However, even if we consider only the repolarization
phase (JT interval), disopyramide still has a significant
prolonging effect. All the cardiomyocytes analyzed in
this work were isolated from the subendocardial re-
gion of the basal septum, the most hypertrophied re-
gion in patients with obstructive HCM. If the degree of
cardiomyocyte electrical changes is heterogeneous
across the LV and mirrors the asymmetrical distribu-
tion of hypertrophy, cardiomyocytes from other re-
gions of the LV are likely to be similar to control
cardiomyocytes. Therefore, we constructed a 3-
dimensional model of the whole LV from an obstruc-
tive patient (Figure 6E) where we assumed that the
HCM-specific ion current abnormalities we observed
in isolated cardiomyocytes from septal myectomy
samples (15,23) were limited to the hypertrophied
septal region. In agreement with this assumption, the
spatial dispersion of QTc interval is greatly increased
in patients with HCM with asymmetrical hypertrophy
(47). In this model, we found that disopyramide
shortens the duration of septal AP while slightly pro-
longing the AP of the remaining LV myocardium, ul-
timately resulting in a slight prolongation of the global
QT interval in the reconstructed ECG trace. In line with
that prediction, the average prolongation of QTc in-
terval in patients with HCM with disopyramide (5% to
6%) is lower than the average QT prolongation in
healthy patients taking a similar dose of disopyramide
(10% to 15%) (1,48). The model predicts that dis-
opyramide determines marked reduction of QT
dispersion across the different LV regions, as well as
transmurally. Because the magnitude of the AP-
shortening effect of disopyramide is linearly related
with the AP duration at baseline (Figure 6C), the effect
would be greater in cells with longer AP, globally
reducing the heterogeneity of AP duration among
different LV regions. In line with that, we observed in
patients that the QTc prolonging effect of dis-
opyramide is inversely related to the baseline
QTc interval: patients with an initially longer QTc in-
terval (>457 ms) had a smaller increase in QTc interval
after disopyramide than did patients with shorter
initial QTc interval. Interestingly, spatial QT disper-
sion is a substrate for sustained re-entrant arrhythmias
and is related with the occurrence of nonsustained
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15ventricular tachycardia in patients with HCM (47);
therefore, its reduction by disopyramide could
be antiarrhythmic.
EFFECT ON EARLY AND LATE AFTERDEPOLARIZATIONS:
ANTIARRHYTHMIC POTENTIAL. We observed a reduc-
tion of the cellular triggers of arrhythmias in HCM
cardiomyocytes treated with disopyramide, that is,
EAD and DAD (Figure 3). The risk of EAD is directly
associated with AP prolongation (49). The short-
ening of AP by disopyramide is therefore the main
mechanism behind the reduction of EAD (15). DAD
result from the activation of the electrogenic
(depolarizing) NCX secondary to spontaneous dia-
stolic Ca2þ release from the SR (50). The likelihood
of DAD is therefore increased in all conditions
leading to increased open probability of RyR during
diastole, that is increased SR Ca2þ load, increased
diastolic cytosolic [Ca2þ] or altered intrinsic prop-
erties of the RyR (e.g., phosphorylation by
Ca2þ/calmodulin-dependent protein kinase II). All
these features are present in HCM cardiomyocytes,
explaining the observed increase of DAD with
respect to control cells (15). Interestingly, we
observed that disopyramide reduced diastolic cyto-
solic [Ca2þ] (Figure 2) and SR Ca2þ content and sta-
bilized the closed state of RyR (Figure 5), thus
lowering the likelihood of diastolic Ca2þ waves.
SAFETY OF DISOPYRAMIDE IN CLINICAL PRACTICE. The
multichannel inhibitory effects and the membrane
stabilizing actions of disopyramide in vitro provide an
explanation to the clinical observation that, even
though the drug prolongs QT intervals, it does not
increase arrhythmic propensity in HCM. In a multi-
center study of disopyramide, with a relatively low
dosage, there was a clear trend toward lower sudden
cardiac death mortality in disopyramide-treated pa-
tients with HCM (5). Subsequent studies have shown
that the incidence of sudden cardiac death, appro-
priate ICD discharges or resuscitated cardiac arrest in
a cohort of over 200 patients treated with dis-
opyramide is only 0.3% per year, as evaluated after an
average follow-up of 5 years (4,6). This rate of lethal
or potentially lethal events compares favorably with
the natural history of HCM and even with the long-
term outcome of patients with obstructive HCM
treated with surgical myectomy (51). Disopyramide
appears to have an intrinsic safety mechanism in
HCM cells, whereby the QT prolonging effects are
most evident in cells with short baseline AP duration
and are overcome by QT shortening effects in those
with longer AP. Combined with its potential protec-
tive action from ventricular arrhythmias, this pro-
vides disopyramide with a very favorable profile for
clinical use in HCM. Following the results of thiswork, an investigation with prolonged arrhythmia
event monitoring before and after disopyramide
would be of great interest. In addition to its beneficial
electrophysiological effects described herein, the
hemodynamic effect of gradient reduction is likely to
be antiarrhythmic by decreasing myocardial work and
supply-demand ischemia, and by improving myocar-
dial energy efficiency. Despite the demonstrated
electrophysiologic and clinical safety, we continue to
believe it is prudent to avoid concomitant adminis-
tration of other QT-prolonging medications along
with disopyramide (Figure 7).
STUDY LIMITATIONS. First, in this work, we only
studied cardiomyocytes isolated from the hypertro-
phied upper septum; therefore, we could not verify
whether the effects of disopyramide are different in
cells from other less affected regions. Second, dis-
opyramide hastens the decay of Ca2þ transients
and accelerates myocardial relaxation in HCM
myocardium (Figures 1 and 2), as a consequence of the
increased Ca2þ-extrusion activity of NCX (15,18)
(Figure 5). Such effect is expected to improve dia-
stolic function in vivo. However, echocardiographic
data from our patients did not show any amelioration
of active mechanical diastolic parameters (Table 4).
This is in line with previous results obtained in pa-
tients with HCM using ranolazine, which failed to
improve diastolic parameters, despite reducing
circulating pro–B-type natriuretic peptide (52). Third,
we did not directly evaluate the effects of dis-
opyramide on atrial or ventricular arrhythmia burden
in the patients included in the clinical study, as no
ambulatory ECG monitoring was performed. Fourth,
our results do not provide clear mechanistic insights
into why up to 30% of patients with obstructive HCM
started on disopyramide are nonresponders. Given
the relatively small number of patient samples, we
could not observe a subset of them showing minimal
or no response to the drug. However, as the response
to disopyramide appears to be higher in cells with
more pronounced electrophysiological changes (e.g.,
increase of INaL and decrease of IK [see Figures 6C and
6D]) and the severity of electrical remodeling varies
substantially among different patients (as we previ-
ously reported in [15]), interpatient variability in the
severity of cellular abnormalities may underlie the
differences in the clinical response to disopyramide.
Moreover, prior clinical investigations have shown
that a subset of patients with a combination of both
high resting gradients >85 mm Hg and long anterior
mitral leaflets $33 mm Hg have a suboptimal
response to oral disopyramide due to a combination
of adverse anatomy and excessive leaflet slack (6).
Fifth, due to the limited number of patient samples
FIGURE 7 Effects of Disopyramide in HCM Cardiomyocytes
(Top) In HCM cardiomyocytes, ICa-L and INaL are increased, while IK is markedly decreased, leading to prolonged APs; Na overload impairs NCX, contributing to
cytosolic Ca-overload. (Bottom) Disopyramide inhibits INa-peak (INaP), INaL, ICa-L and IK, while also stabilizing ryanodine receptors. These effects lead to shortening of
APs. Moreover, normalization of NCX function and ICa-L inhibition and RyR stabilization contribute to reduce diastolic Ca and systolic Ca-release, determining negative
inotropic effects. APs ¼ action potentials; HCM ¼ hypertrophic cardiomyopathy; ICa-L ¼ L-type Ca current; IK ¼ delayed-rectifier K current; INaL ¼ Late Na current;
NCX ¼ Naþ/Ca2þ exchanger; RyR ¼ ryanodine receptor.
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17and incomplete genetic data (Online Table 1), we were
unable to correlate specific parameters of drug
effectiveness with the different disease-causing
mutated genes. As disopyramide does not directly
interacts with sarcomeres (Figure 1), we believe it is
unlikely that mutations in different sarcomeric genes
affect the efficacy of the drug. Moreover, we previ-
ously observed that the degree of electrical abnor-
malities at cardiomyocyte level is similar in samples
from patients carrying mutations in MYH7 and in
MYBPC3 and patients with no sarcomeric gene mu-
tations. As disopyramide targets ion channels, these
results support the idea that the effects of the drug do
not vary depending on the different causing muta-
tions. Sixth, one-half of the patients with HCM
included in this study were under disopyramide
therapy prior to surgery (Online Table 1); as it is un-
known whether long-term disopyramide treatment
alters the expression or function of ion channels and
other functional cardiomyocyte proteins, we cannot
exclude that this may have influenced the results of
this study.PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: The
effects of disopyramide in the hearts of patients with
HCM are mediated by the combined inhibition of peak
Naþ current, INaL, Ca2þ channels, Kþ channels, and RyR.
Such multichannel inhibition explains the marked
negative inotropic effect of the drug, which is responsible
for the reduction of LV outflow gradients in patients with
obstructive HCM. Moreover, these combined actions also
result in shortening of the HCM cardiomyocyte AP,
improvement of intracellular Ca overload, reduction of
afterdepolarizations, and smaller dispersion of repolari-
zation, conferring additional antiarrhythmic potential.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Our
translational study provides the mechanistic explanation
for the safety and efficacy of disopyramide in patients with
obstructive HCM, which has been confirmed by over 40
years of clinical use. These results support the idea that
disopyramide treatment can be safely initiated in the
outpatient setting and requires only an initial evaluation of
the changes in QTc interval, which are usually rather small
and are not associated with an increased risk of
arrhythmias.
TRANSLATIONAL OUTLOOK 1: The negative inotropic
effect of disopyramide does not depend on direct
inhibition of myofilament contraction. As such, it does not
appear incompatible with the new class of allostericCONCLUSIONS
Disopyramide emerges as a safe drug due to its
multichannel blocking effects. Disopyramide is an
effective negative inotrope that avoids interference
with sarcomere protein function. This promises to
enrich the pharmacological armamentarium to con-
trol obstruction as well as arrhythmias. Indeed, our
data suggest a potential protective effect of dis-
opyramide from ventricular arrhythmias mediated by
suppression of afterdepolarizations and transmural
re-entry; future studies aimed at evaluating the
antiarrhythmic potential of disopyramide in patients
with HCM are warranted. The results of this study
provide a measure of reassurance to clinicians still
concerned with the use of disopyramide in a complex
structural disease such as HCM.
ADDRESS FOR CORRESPONDENCE: Dr. Raffaele
Coppini, Department NeuroFarBa, University of
Florence, Viale G. Pieraccini 6, 50139 Firenze, Italy.
E-mail: raffaele.coppini@unifi.it.myosin modulators currently under investigation
(mavacamten). As disopyramide and mavacamten act on
different targets, they could potentially be combined
with synergic effects, if the efficacy and safety of
mavacamten on long-term administration is confirmed in
the ongoing phase III studies.
TRANSLATIONAL OUTLOOK 2: The use of drugs that
inhibit hERG channels and cause drug-related QT
prolongation are commonly considered to be more
dangerous in patients with pre-existing structural heart
disease, such as HCM. This assumption does not take into
consideration the disease-related changes in cardiomyo-
cyte ion channel expression. In HCM, the baseline
expression of hERG channels is reduced, so the QT
prolonging effect of disopyramide (and probably that of
other hERG blocking drugs) is reduced. Paradoxically, the
proarrhythmic consequences of hERG-blocking
QT-prolonging drugs might be less severe in hearts with
structural disease and profound electrical remodeling, as
compared with healthy hearts.
TRANSLATIONAL OUTLOOK 3: The promising
antiarrhythmic properties of disopyramide in vitro
suggest a role for clinical use also in patients without
obstructive HCM, such as, as a less toxic alternative to
amiodarone for control of atrial fibrillation.
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